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Abstract
Introduction. Gastrointestinal stromal tumors (GISTs) are
rare and account for 0.1%–3% of all gastrointestinal neo-
plasms. GISTs are most commonly located in the stomach
(60%) and 20%–25% are malignant, with metastases in-
volving the peritoneum or the liver. Cystic liver metastases
are extremely rare. Only two previous cases of patients with
cystic liver metastases, prior to treatment with imatinib me-
sylate, have been described so far. Case report. We re-
ported a 52-year-old woman presented with a history of ab-
dominal fullness and discomfort. Clinical examination re-
vealed two palpable masses, first in the right upper abdo-
men and second left to the umbilicus. Examinations re-
vealed 4 cystic metastases in the liver, 3 in the right lobe (in-
cluding a huge one measuring 20.5 u 16 cm), and 1 in the
left lobe, together with a primary tumor on the greater cur-
vature of the stomach. Gastric tumor was removed with a
Billroth II gastrectomy. Partial excision of the largest liver
metastasis was performed for histopathology. Immunohis-
tochemistry confirmed the diagnosis of a GIST in both tis-
sue samples. After an uneventful recovery the patient was
commenced on imatinib mesylate therapy. The patient re-
mainsed symptom-free at 24 months follow-up. Conclu-
sion. This was the third reported case of gastric GIST with
giant cystic liver metastases present prior to treatment with
imatinib mesylate. Although extremely rare, GISTs may pre-
sent with cystic liver metastases prior to treatment with
imatinib mesylate, and should be considered in the differen-
tial diagnoses of patients with liver cysts of uncertain aetiol-
ogy.
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Apstrakt
Uvod. Gastrointestinalni stromalni tumori (GIST) su retki
tumori koji ÿine ukupno 0,1–3% svih gastrointestinalnih neo-
plazmi. Najÿešýa lokalizacija GIST je u želucu (60%). Oko
20–25% ovih tumora je maligno, dok su metastaze najÿešýe
lokalizovane po peritoneumu ili u jetri. Pojava cistiÿnih meta-
staza GIST u jetri je veoma retka i do sada su u literaturi opi-
sana samo dva bolesnika sa ogromnim cistiÿnim metastazama
GIST u jetri pre leÿenja imatinib mesilatom. Prikaz bolesni-
ka. Prikazana je bolesnica stara 52 godine, koja se javila leka-
ru zbog oseýaja napetosti u trbuhu. Kliniÿkim pregledom na-
Āena su dva palpabilna tumefakta ispod desnog rebarnog luka
i paraumbilikalno sa leve strane. Kompletnom radiološkom
pretragom utvrĀeno je postojanje stromalnog tumora velike
krivine želuca i ÿetiri krupne cistiÿne promene u jetri, tri u de-
snom i jedna u levom lobusu jetre. Najveýa od ovih promena
bila je dimenzija 20,5 u 16 cm. Bolesnica je operisana kada je
uraĀena resekcija želuca tipa Billroth II i parcijalna ekscizija
najveýe promene iz desnog lobusa jetre. Patohistološka i
imunohistohemijska analiza potvrdile su dijagnozu GIST u
želucu i jetri. Nakon uspešnog postoperativnog oporavka or-
dinirana je terapija imatinib mesilatom na koju je bolesnica
dobro reagovala. Dve godine nakon operacije bolesnica je
dobro i bez znakova recidiva bolesti. Zakljuÿak. Ovo je tek
treýi opisani bolesnik sa gastriÿnim GIST, sa ogromnim cisti-
ÿnim metastazama u jetri pre leÿenja imatinib mesilatom. Ma-
da veoma retko, GIST se mogu prezentovati sa cistiÿnim
metastazama u jetri pre leÿenja imanitib mesilatom i treba da
budu razmotreni u diferencijalnoj dijagnozi bolesnika sa cis-
tama u jetri nepoznate etiologije.
Kljuÿne reÿi:
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Introduction
Gastrointestinal stromal tumors (GISTs) are rare and
account for 0.1%–3% of all gastrointestinal tumors, and
5.7% of gastrointestinal sarcomas 
1, 2. They are mesenchymal
in origin, defined as c-kit (CD 117) positive tumors, and
have a characteristic set of histological features including
spindle or epitheloid cells 
3.
Around 20%–25% of gastric GISTs are malignant and
frequently metastasize to the liver and peritoneum. Liver
metastases are typically solid, and cystic lesions are ex-
tremely rare in these patients at presentation 
4, 5. Cystic liver
metastases appear in colorectal, ovarian and pancreatic mu-
cinous adenocarcinomas, usually as a result of an accumula-
tion of mucin/serous fluid produced by the tumor itself or
from cystic degeneration consequent to ischemic necrosis or
infarction of the tumor mass 
4. Solid GIST liver metastases
can also develop cystic changes following targeted therapy
with imatinib mesylate, which inhibits c-kit and causes tu-
mor shrinkage 
6.
Only two patients with cystic GIST liver metastases
prior to treatment with imatinib mesylate have been de-
scribed so for. This is the third patient with gastric GIST and
huge cystic liver metastases.
Case report
A 52-year-old woman with no significant past medical
history presented to our unit with a 2-month history of full-
ness and discomfort in the right upper abdomen. On exami-
nation the patient had a large spherical, painless, fluctuant
mass palpable in the right upper abdomen, extending up be-
hind the right costal margin. Another, smaller, hard, painless
and mobile mass was also found to the left of the umbilicus.
There was no splenomegaly or ascites, and there were no di-
lated veins on the abdominal wall. The patient had an ele-
vated white blood cells (WBC) (18.9 u 109/L), mild anemia
and mild thrombocytosis (516 u 109/L). Blood proteins were
elevated (93 g/L) as were fibrinogen (9.0 g/L), alkaline
phosphatase (199 u/L) and Ȗ-GT (120 u/l). All other labora-
tory data including tumor markers (ALP, CA 19-9, CA 72-4,
CEA) were within normal limits.
Ultrasonography showed that much of the right lobe of
the liver was taken up by 3 cystic lesions. The largest of
these measured 20.5 cm u 16 cm and contained several tissue
layers (Figure 1); two smaller cysts measuring 5.7 cm u 6.3
cm and 6.7 cm u 8 cm were located in segments VII and VIII
of the liver. A fourth cyst measuring 3 cm in diameter cm
was present in the left liver lobe. A gastric tumor measuring
9.5 u 7.5 cm u 6.5 cm was present in the left mesogastrium.
Computed tomography scan confirmed the ultrasonography
findings (Figures 2, 3 and 4).
We performed the operation throuph right subcostal
laparotomy. A firm, mobile, rough tumor was found attached
to the greater curvature of the antral part of the stomach. The
tumor had not created any defect of the gastric mucosa and
was removed by way of a Billroth II gastrectomy. Frozen
section histology of the tumor was suggestive of GIST. The
Fig. 1 – Ultrasound showing a giant cyst within the right
lobe of the liver containing several tissue layers
Fig. 2 – Computed tomography scan showing a giant cyst of
the right lobe of the liver, and a part of the segment VIII
smaller cyst
Fig. 3 – Computed tomography scan showing a frontal
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largest of the previously identified cystic lesions of the liver
contained old blood and a jellylike material. The well of the
cyst wall was excised and sent for histology.
The antral gastric tumor hads predominantly extramural
growth, and measured up to 95 mm in diameter. Macro-
scopically, it appeared pseudocystic as most of the central
areas were necrotic and hemorrhagic. This soft, fragile inter-
nal tissue was surrounded by a more firm, partly sclerotic
and calcified pseudocapsule. Histology revealed mesenchy-
mal neoplastic proliferation which was mostly hypercellular
and epithelioid, but with many additional microcystic and
pseudohemangiomatous areas (Figure 5a). The periphery
contained the areas of mixed spindle and epithelioid cells
with a vacuolar and sclerosing appearance, suggestive of
gastric GIST. The liver cyst specimen had a very thin rim of
neoplastic tissue at its periphery, which was sharply demar-
cated from hepatic parenchyma (Figure 5b). Its histology
was identical to that the gastric tumor confirming that it was
a liver metastasis.
Immunohistochemistry showed strong PDGFRA im-
munostaining of the epitheliod areas but only focal and weak
"dot-like" cytoplasmic CD117 immunostaining in the mixed
spindle and epithelioid areas, in both the primary and secon-
dary lesions (Figure 5c and d). Vimentin immunostaining
was also positive, however CD34, desmin, ĮSMA, S-100
protein, WT-1, calretinin and markers for other epithelial,
neuroendocrine and other non-mesenchymal markers were
all negative.
The patient’s postoperative recovery was uneventful.
Following histological confirmation of a malignant GIST of
the stomach with cystic liver metastases the patient was
commenced on imatinib mesylate treatment, and remainsed
clinically well at 24 months.
Disussion
GISTs encompass a wide spectrum of tumors with
varying locations and biological potentials. Previously classi-
fied as leiomyomas, leiomyosarcomas, neurofibromas and
Fig. 4 – Computed tomography scan showing a cyst like
gastric gastrointestinal stromal tumors in the left
mesogastrium
Fig. 5 – Microcystic pseudohemangiomatous appearance of the predominantly epithelioid gastric gastrointestinal stromal
tumors (A) and its cystic liver metastasis (B), which revealed diffuse strong PGFRA immunoexpression (C) and weak focal
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schwanomas, GISTs are now known to be quite different
both histologically and immunohistochemically 
6. They pre-
dominantly affect middle-aged and older patients (median
age of 55–60 years) 
3, and while they can occur in different
parts of gastrointestinal tract, they most commonly occur in
the stomach (60% of cases) and small intestine (35%); they
can also occur in the rectum and other parts of gastrointesti-
nal tract, and in those tissues in close proximity to them 
1, 3, 4.
GISTs are believed to originate from the intestinal cells of
Cajal or related stem cells, and can be divided histologi-
cally into 4 spindle cell (70%) and 4 epitheloid variant
(30%) subgroups 
3.
A significant proportion of GISTs are malignant, how-
ever differences exist according to primary tumor location 
7, 8;
20%–25% of gastric and 40%–50% of small intestine GISTs
are malignant 
3. Metastases frequently occur in the peritoneum
and liver, and only rarely involve the bones, soft tissues and
skin; lymph node and lung metastases are extremely rare.
Metastases can develop up to 10–15 years after primary sur-
gery, and thus a life-long clinical follow-up is mandatory 
3.
GIST liver metastases are typically solid, and cystic le-
sions are extremely rare in these patients at presentation 
4, 5.
In 2003 Zonios et al. 
5 reported a 73-year-old woman with
gastric GIST who presented with low grade fever, weight
loss, left-quadrant pain and multiple cyst-like hepatic metas-
tases, while in 2009 Jain et al. 
4 presented a 50-year-old man
with gastric GIST who had a 12 cm u 9 cm cystic liver me-
tastasis. Both these patients had cystic GIST liver metastases
prior to any treatment.
Solid GIST liver metastases are known to develop cys-
tic changes as a result of targeted therapy with imatinib me-
sylate, which inhibits c-kit and causes tumor shrinkage 
6. In-
deed these morphological changes are now regarded as a
positive prognostic sign, as the overall survival is signifi-
cantly better in those patients developing these cystic
changes following imatinib mesylate treatment 
1.
This is only the third documented case of gastric GIST
with cystic metastases present prior to any treatment. The
presented patient had multiple cystic liver metastases and the
largest such reported lesion.
Conclusion
Although extremely rare, GISTs may present with cys-
tic liver metastases prior to treatment with imatinib mesylate,
and should be considered in the differential diagnoses of pa-
tients with liver cysts of uncertain etiology.
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